Related Experiment Video

Updated: May 22, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

Myostatin is a novel tumoral factor that induces cancer cachexia

Sudarsanareddy Lokireddy1, Isuru Wijerupage Wijesoma, Sabeera Bonala

  • 1School of Biological Sciences, Nanyang Technological University, Singapore.

The Biochemical Journal
|May 25, 2012
PubMed

Insights

Tumoral myostatin secreted by colon cancer cells drives muscle wasting in cancer cachexia. Blocking myostatin in cell cultures prevented muscle atrophy, highlighting its role in this condition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Physiology

Background:

  • Cancer cachexia involves skeletal muscle wasting driven by humoral and tumoral factors.
  • While humoral factors like TNFα and IL-6 are known, tumoral factors contributing to muscle atrophy remain less understood.
  • Characterizing the cancer cell secretome is crucial for identifying these tumoral factors.

Purpose of the Study:

  • To identify tumoral factors secreted by C26 colon cancer cells that contribute to cancer-induced skeletal muscle wasting.
  • To investigate the molecular mechanisms by which these factors induce muscle atrophy.
  • To assess the therapeutic potential of targeting identified tumoral factors.

Main Methods:

  • Secretome analysis of C26 colon cancer cells.
  • Treatment of differentiated C2C12 myotubes with C26 conditioned medium (CM).
  • Assessment of muscle-specific E3 ligases (atrogin-1, MuRF1), ubiquitin-proteasome pathway activity, signaling pathways (ActRIIB/Smad, NF-κB, IGF-I/PI3K/Akt), and mitochondrial content.
  • Use of myostatin antagonists in cell culture experiments.
  • Analysis of skeletal muscles from C26 tumor-bearing mice.

Main Results:

  • Myostatin was identified as a key factor abundantly secreted by C26 colon cancer cells.
  • C26 CM induced myotubular atrophy, up-regulated atrogin-1 and MuRF1, and enhanced ubiquitin-proteasome activity.
  • C26 CM activated ActRIIB/Smad and NF-κB signaling, while inhibiting IGF-I/PI3K/Akt signaling.
  • Myostatin antagonists blocked C26 CM-induced muscle wasting in vitro.
  • C26 CM induced autophagy-lysosome pathway and reduced mitochondrial number in myotubes, findings mirrored in C26 tumor-bearing mice.

Conclusions:

  • Tumoral myostatin secreted by C26 colon cancer cells is a significant contributor to cancer-induced skeletal muscle wasting.
  • Myostatin signaling mediates muscle atrophy through the activation of specific molecular pathways and the ubiquitin-proteasome system.
  • Myostatin also influences the autophagy-lysosome pathway and mitochondrial dynamics in muscle cells during cancer cachexia.
  • Targeting tumoral myostatin presents a potential therapeutic strategy for combating muscle wasting in cancer cachexia.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...